The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

For many, these price reductions may represent a critical step in improving access to essential medications, especially as ...

Medicare beneficiaries will see major pricing shifts as federal negotiations reshape how costly prescription drugs are paid ...

As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review. The Medicines and Healthcare products ...

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for ...

A plate of freshly baked cookies, a glass of perfectly garnished eggnog. For many, these images may conjure up warm memories ...

STUART, Fla., Dec. 16, 2025 /PRNewswire/ -- The United States is entering a period of significant disruption in healthcare coverage, according to health policy observers, with millions of Americans ...

A 17-year-old worker died at a pork producer in Nebraska run by the governor’s family. Two investigations later, the boy’s ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

The 2025 AAO‐HNSF adult sinusitis guideline, an update of the 2015 guideline, offers evidence-based recommendations on ...

Shamim earns Tk75,000 a month working at a private company in Dhaka. Yet even that income is no longer enough to keep his ...